Seattle Genetics (NASDAQ:SGEN) Target Raised by Needham & Company LLC to $188.00

0
36
Close-up Of A Person Hand Doing Property Tax Calculation With House Model On The Table

Seattle Genetics stock has undergone multiple analysts rating changes in the recent past.  Seattle Genetics stock Target Raised by   Needham & Company LLC on 6/30/2020. In a note to investors, the firm issued a new target price of $188.00. The analysts previously had $163.00 target price. Needham & Company LLC’s price target would indicate a potential upside of 14.38% from the stock’s previous close.

Shares of Seattle Genetics traded up $1.48 on Tuesday, reaching $165.85. 788013 shares of the stock traded hands, compared to its average volume of 1323512. Shares of were trading at $165.85 on Tuesday. The firm’s 50 day moving average is $$155.58 and its 200 day moving average is $119.32.Seattle Genetics  has a 12 month low of $164.09 and a 12 month high of $175.64. While on yearly highs and lows, Seattle Genetics today has traded high as $169.37 and has touched $164.09 on the downward trend.

Seattle Genetics Earnings and What to expect: 

Seattle Genetics last announced its quarterly earnings data on April 30th, 2020. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.17. The company earned $234.51 million during the quarter, compared to the consensus estimate of $207.59 million. Its quarterly revenue was up 20.1% compared to the same quarter last year. Seattle Genetics has generated ($1.33) earnings per share over the last year. Seattle Genetics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, July 21st, 2020 based off prior year’s report dates.

Earnings for Seattle Genetics are expected to grow in the coming year, from ($2.80) to ($0.84) per share. The P/E ratio of Seattle Genetics is -88.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Seattle Genetics is -88.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Seattle Genetics has a P/B Ratio of 15.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 31.10%
  • On 6/19/2020 EVP Jean I. Liu Sell 9,877 at average share price of $165.00 which equates to $1,629,705.00 in money value.
  • On 6/17/2020 Insider Roger D. Dansey Sell 2,162 at average price of  $158.89 with total value of : Not Data Available
  • On 6/15/2020 Insider Roger D. Dansey Sell 4,984 at average price of  $157.15 with total value of : $783,235.60
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Seattle Genetics

  • 6/30/2020 – Seattle Genetics had its price target raised by analysts at SVB Leerink LLC from $155.00 to $167.00. They now have an “outperform” rating on the stock.
  • 6/26/2020 – Seattle Genetics had its price target raised by analysts at Oppenheimer Holdings Inc. from $175.00 to $200.00. They now have an “outperform” rating on the stock.
  • 5/31/2020 – Seattle Genetics is now covered by analysts at Oppenheimer Holdings Inc.. They set a “buy” rating and a $175.00 price target on the stock.
  • 5/27/2020 – Seattle Genetics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • See More Analyst Rating at: RATING

Other rating updates by Needham & Company LLC: 

  • 6/30/2020 – Intercept Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $150.00 to $100.00. They now have a “buy” rating on the stock.
  • 6/30/2020 – Gilead Sciences had its “hold” rating re-affirmed by analysts at Needham & Company LLC.
  • 6/30/2020 – Xilinx had its “hold” rating re-affirmed by analysts at Needham & Company LLC.
  • 6/30/2020 – Verrica Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $20.00 to $17.00. They now have a “buy” rating on the stock.
  • See More Analyst Rating at: RATING

Seattle Genetics (NASDAQ:SGEN) Moving Average Technical Analysis

5 day Moving Average is $$165.64 And 5 day price change is -$5.55 (-3.24%)  with average volume for 5 day average is 1,004,109. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $159.05 and 20 day price change is $4.76 (2.96%) and average 20 day moving volume is 1,190,632. 50 day moving average is $155.58  and 50 day price change is $23.03 ( 16.16%)  and with average volume for 50 days is : 1,368,755. 200 day moving average is $119.32  and 200 day price change is $94.95 (134.43%)  and with average volume for 200 days is : 1,213,353.

See More Analyst Rating at: RATING